Dusquetide Granted Orphan Drug Status for Behçet Disease The FDA has granted Orphan Drug designation to dusquetide (SGX945) for the treatment of Behçet disease.

#Dusquetide is part of a new class of short, synthetic peptides known as innate defense regulators.

Read More: www.gastroenterologyadvisor.com/news/dusquetide-granted-...

FDA Approves Soligenix's Dusquetide for Behçet's Disease: A Milestone in Rare Disease Treatment Soligenix has received orphan drug designation for dusquetide, marking a significant advance in the treatment of Behçet's Disease after promising Phase 2 results.

FDA Approves Soligenix's Dusquetide for Behçet's Disease: A Milestone in Rare Disease Treatment #USA #Princeton #Soligenix #Behçet's_Disease #dusquetide